Talk

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Explore ioCells
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

bit.bio

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal 

SVP Alliance Management

bit.bio 

Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

bit.bio

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal 

SVP Alliance Management

bit.bio 

Listen to our talk at ELRIG Drug Discovery Digital to learn how bit.bio’s opti-ox  technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.

 

Explore ioCells

Related pages

News Read our latest updates and press coverage
Our platform Discover the cell coding platform behind our cells
Join us Explore the latest roles at bit.bio